Pharma

Your Article Summary

See Latest Articles

SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
Corporate News Releases - The Healthcare Sales & Marketing Network, 09/08/06

Amylin Pharmaceuticals, Inc. announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN (pramlintide acetate) to an established regimen of basal insulin glargine (with or without oral antidiabetic agents) in patients with type 2 diabetes who have not progressed to mealtime insulin therapy

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials